This week, one of Switzerland’s wealthiest family dynasties just made $2.9 billion after selling shares in a pharmaceutical company. But where’s all the money going? Probably to help alleviate tensions between family members and the management of the various foundations/investment/holding vehicles connected to the dynasty.
Subscribe
You will need a Premium+ Subscription to read this article.
Exclusive news, analysis and research on global family enterprise and private investment offices
Already have an account? Sign in
Already have an account? Sign in
You've reached the end.
Continue reading free articles by registering as a Member.
Or choose a Premium Plan.
Already have an account? Sign in